BIOCON BIOLOGICS ITALY S.R.L.
BALANCE SHEET AS AT MARCH 31, 2026
(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Notes	March 31, 2026	March 31, 2025
ASSETS			
Current assets			
Financial assets			
(i) Trade receivables	1	194	312
(ii) Cash and cash equivalents	2	367	484
Other current assets	3	29	12
		590	**808**
TOTAL		**590**	**808**
EQUITY AND LIABILITIES			
Equity			
Equity share capital	4	15	15
Other equity	5	46	19
Total equity		**61**	**34**
Current liabilities			
Financial liabilities			
Trade payables	6	312	607
Income-tax liability (net)		17	7
Provisions	7	8	7
Other current liabilities	8	192	153
Total current liabilities		**529**	**774**
TOTAL		**590**	**808**

BIOCON BIOLOGICS ITALY S.R.L.
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026
(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Notes	Year ended March 31, 2026	Year ended March 31, 2025
Income			
Revenue from operations	9	1,270	546
Other operating income		1	-
Total revenue		**1,271**	**546**
Employee benefits expense	10	874	377
Other expenses	11	336	143
Total expenses		**1,210**	**520**
Profit before tax		**61**	**26**
Tax expense			
Current tax		34	7
Total tax expense		**34**	**7**
Profit for the period		**27**	**19**

BIOCON BIOLOGICS ITALY S.R.L.
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026
(All amounts in EUR Thousands, except share data and unless otherwise stated)

		Year ended March 31, 2026	Year ended March 31, 2025
I	**Cash flows from operating activities**		
	Profit after tax	**27**	**19**
	Adjustments to reconcile profit before tax to net cash flows:		
	Interest income	(1)	-
	Tax expense	34	7
	Operating profit before working capital changes	**60**	**26**
	Movements in working capital		
	Decrease/(Increase) in trade receivables	118	(297)
	(Increase) in loans and advances and other assets	(17)	(12)
	(Decrease)/Increase in trade payable, other liabilities and provisions	(255)	767
	Cash (used in)/generated from operations	**(94)**	**484**
	Direct taxes paid	(24)	-
	Net cash flow (used in)/generated from operating activities	**(118)**	**484**
II	**Cash flows from investing activities**		
	Interest received	1	-
	Net cash flow generated from investing activities	**1**	**-**
III	**Cash flows from financing activities**		
	Proceeds from issue of equity shares	-	-
	Net cash flow generated from financing activities	**-**	**-**
IV	**Net (decrease)/increase in cash and cash equivalents (I + II + III)**	**(117)**	**484**
V	Effect of exchange differences on cash and cash equivalents held in foreign currency	-	-
VI	Cash and cash equivalents at the beginning of the year	484	-
VIII	**Cash and cash equivalents at the end of the year (IV + V + VI)**	**367**	**484**
	Reconciliation of cash and cash equivalents as per statement of cash flow		
	Cash and cash equivalents		
	Balances with banks - on current accounts	367	484
	Total cash and cash equivalents [Refer note 2]	**367**	**484**

BIOCON BIOLOGICS ITALY S.R.L.
Notes to financial statements for the year ended March 31, 2026
(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
1. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	194	312
	194	**312**
2. Cash and cash equivalents		
Balances with banks:		
On current accounts	67	484
Deposit accounts	300	-
	367	**484**
3. Other current assets		
Prepayments	1	-
Other assets	28	12
	29	**12**
4. Share capital		
Authorised		
Issued, subscribed and fully paid-up		
1 Equity share of EUR 15,000 each	15	15
	15	**15**
5. Other equity		
Surplus in the statement of profit and loss		
Balance as per the last financial statements	19	-
Profit for the year	27	19
Net surplus in the statement of profit and loss	**46**	**19**
Total other equity	**46**	**19**
6. Trade payables	**312**	**607**
7. Provisions		
Current		
Compensated absences	8	7
	8	**7**
8. Other liabilities		
Current liabilities		
Statutory liabilities	192	153
	192	**153**

BIOCON BIOLOGICS ITALY S.R.L.
Notes to financial statements for the year ended March 31, 2026
(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
9. Revenue from operations		
Sale of Services		
Support service cross charge to Group Companies	1,270	546
	1,270	**546**
10. Employee benefits expense		
Salaries, wages and bonus	874	377
	874	**377**
11. Other expenses		
Rates and taxes	21	6
Rent	2	4
Legal and professional fees	50	51
Travelling and conveyance	178	50
Sales promotion expenses	41	12
Printing and stationery	18	16
Communication expenses	2	-
Miscellaneous expenses	24	4
	336	**143**